Outputs (2)

Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination (2021)
Journal Article
Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tanasescu, R., & Evans, J. R. (2021). Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Annals of Neurology, 90(2), 315-318. https://doi.org/10.1002/ana.26144

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS-CoV-2 vaccine. This rare neurol... Read More about Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.

Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing (2020)
Journal Article
Astbury, S., Nunes Soares, M. M. D. C., Peprah, E., King, B., Jardim, A. C. G., Shimizu, J. F., …McClure, P. (2020). Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. Journal of Clinical Virology, 129, Article 104483. https://doi.org/10.1016/j.jcv.2020.104483

© 2020 Background: Effective drug regimens for the treatment of hepatitis B virus (HBV) infections are essential to achieve the World Health Organisation commitment to eliminate viral hepatitis by 2030. Lamivudine (3TC) is widely used in countries wi... Read More about Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing.